You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patients characteristics at commencement of antiretroviral therapy in the HIV Centre Belgrade (HCB) and Royal Free Hospital (RFH) London

From: Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study

   HCB RFH P-value
Number   597 (100 %) 1763 (100 %)  
Gender Male 478 (80 %) 1234 (70 %) <0.0001
Female 119 (20 %) 529 (30 %)  
Age Median (IQR) 38 (32-44) 36 (32-43) 0.05
Ethnicity White 597 (100 %) 892 (51 %) <0.0001
Black African 0 (0 %) 530 (30 %)  
Other 0 (0 %) 341 (19 %)  
Risk for HIV Acquisition Sex between men 218 (37 %) 850 (48 %) <0.0001
Heterosexual 155 (26 %) 839 (48 %)  
Injecting Drug Use 90 (15 %) 49 (3 %)  
Other 134 (22 %) 25 (1 %)  
Calendar year 2003-2005 268 (45 %) 682 (39 %)  
2006-2008 126 (21 %) 648 (37 %)  
2009-2012 203 (34 %) 433 (25 %)  
Previous AIDS Yes 361 (61 %) 337 (19 %) <0.0001
CD4+ T-cells count (cells/mm3) Median (IQR) 177 (85, 298) 238 (123, 339) <0.0001
(N = 575)* (N = 1519)**
pVL (log10 copies/mL) Median (IQR) -+ 4.9 (4.3, 5.4) (N = 1466)*** -
Previous TB diagnosis Yes 28 (5 %) 127 (7 %) 0.03
HCV Ab status Positive 131 (22 %) 88 (5 %) <0.0001
Negative 466 (78 %) 1005 (57 %)  
Unknown 0 (0 %) 688 (39 %)  
HBV sAg status Positive 78 (13 %) 53 (3 %) <0.0001
Negative 56 (87 %) 1005 (57 %)  
Unknown 0 (0 %) 705 (40 %)  
  1. IQR = inter quartile range; TB = tuberculosis; pVL = plasma HIV RNA viral load; HCV Ab = Hepatitis C virus antibody; HBV sAg = hepatitis B virus surface antigen; *available for 575 patients, **available for 1519 patients ***available for 1466 patients; + pre-cART pVL measurements not performed at HCB